Bicara Therapeutics (BCAX) to Release Earnings on Tuesday

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter.

Bicara Therapeutics Price Performance

Bicara Therapeutics stock traded down $0.82 during mid-day trading on Friday, hitting $13.00. 352,032 shares of the company were exchanged, compared to its average volume of 310,066. The business has a fifty day moving average of $14.40. Bicara Therapeutics has a 1-year low of $11.10 and a 1-year high of $28.09.

Analysts Set New Price Targets

Several research firms have recently weighed in on BCAX. Wedbush reaffirmed an "outperform" rating and set a $31.00 price objective on shares of Bicara Therapeutics in a report on Wednesday, February 12th. HC Wainwright lifted their target price on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a "buy" rating in a research note on Monday, January 27th. RODMAN&RENSHAW upgraded Bicara Therapeutics to a "strong-buy" rating in a research report on Tuesday, November 5th. Finally, Rodman & Renshaw assumed coverage on Bicara Therapeutics in a research report on Tuesday, November 5th. They issued a "buy" rating and a $48.00 price objective for the company. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $41.20.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.